Status:
UNKNOWN
Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation
Lead Sponsor:
Texas Cardiac Arrhythmia Research Foundation
Conditions:
Thromboembolic Events
Eligibility:
All Genders
Brief Summary
Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events. However, some patients a...
Detailed Description
1. BACKGROUND Atrial fibrillation (AF) is known to be a leading cause of thrombo-embolic (TE) events (1).The left atrial appendage (LAA), an embryological remnant of the primitive left atrium, has bee...
Eligibility Criteria
Inclusion
- \- i. male or female over 18 years of age at the time of enrollment ii. have received LAAI procedure iii. Discontinued OAC for any duration
Exclusion
- i. end-stage renal or liver disease ii. on oral anticoagulation for any other condition iii. pregnant, breastfeeding, or unwilling to provide consent iv. presence of other conditions or abnormalities that in the opinion of the Investigator would compromise the quality of the data
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04115436
Start Date
October 1 2019
End Date
October 1 2020
Last Update
October 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Cardiac Arrhythmia Institute
Austin, Texas, United States, 78705